Recent Patents on Metalloproteinases as Biomarkers in Osteoarthritis Diagnosis and Treatment
Raymundo Cruz, Magdalena Miranda-Sanchez, David Solis-Garcia and Juan B. KouriAffiliation:
Av. Instituto Politecnico Nacional, 2508 Col. San Pedro Zacatenco C.P. 07360, Apartado postal 14- 740, 07000 Mexico, DF, Mexico.
AbstractOsteoarthritis is a multifactorial joint disease affecting millions of patients all around the world. Some inflammatory mediators as interleukin-1 beta and tumor necrosis factor-alpha, among others, are involved in stimulating the metalloproteinases production in the osteoarthritis disease process. These enzymes degrade all the articular cartilage extracellular matrix components; such as collagen, aggrecan and non-collagen proteins. In osteoarthritis, the expression of metalloproteinases is elevated and some considerable efforts have been made in order to design effective inhibitors of enzymes activity and/or synthesis with the intention of limiting the connective tissues destruction within the joints. As of yet, there are no effective clinical inhibitors; however, published patents employing metalloproteinases as early osteoarthritis biomarkers and/or targets for effective therapies might be able to provide new opportunities to prevent joint destruction related to osteoarthritis.
Aggrecan, biomarkers, cartilage, collagen, metalloproteinases, osteoarthritis, patents.
Download Free Order Reprints Order Eprints Rights and Permissions